A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function

Chemico-Biological Interactions

Volumn 181, Issue 1, 2009, Pages 1-7

  Fang, Lin ^a   Huang, Yao ^b   Hu, Xiaocui ^a   Sun, Lijun ^a   He, Xiaoping ^c   Hu, Huanzhang ^b   Pu, Yingyan ^a   Cao, Xiangrong ^a   Luo, Hongmei ^a   Pan, Shaokun ^a   Gu, Jianzhong ^d   Su, Changqing ^a,b  

^a NANJING NORMAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c JINLING HOSPITAL   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Cancer gene therapy; E1a gene; Neu gene; Oncolytic adenovirus; Rb gene

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOLYTIC ADENOVIRUS; RETINOBLASTOMA PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; FLOW CYTOMETRY; GENES, ERBB-2; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; RETINOBLASTOMA PROTEIN; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 67650686561     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.06.002     Document Type: Article

References (26)

1. Wang X., Su C., Cao H., Li K., Chen J., Jiang L., Zhang Q., Wu X., Jia X., Liu Y., Wang W., Liu X., Wu M., and Qian Q. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol. Cancer Ther. 7 (2008) 1598-1603
2. Hawkins L.K., Lemoine N.R., and Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol. 3 (2002) 17-26
3. Ouchi M., Kawamura H., Urata Y., and Fujiwara T. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin). Invest. New Drugs 27 (2009) 241-245
4. Bazan-Peregrino M., Carlisle R.C., Hernandez-Alcoceba R., Iggo R., Homicsko K., Fisher K.D., Halldén G., Mautner V., Shen Y., and Seymour L.W. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum. Gene Ther. 19 (2008) 873-886
5. Kim J., Kim J.H., Choi K.J., Kim P.H., and Yun C.O. E1A- and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum. Gene Ther. 18 (2007) 773-786
6. Radke J.R., Siddiqui Z.K., Miura T.A., Routes J.M., and Cook J.L. E1A oncogene enhancement of caspase-2-mediated mitochondrial injury sensitizes cells to macrophage nitric oxide-induced apoptosis. J. Immunol. 180 (2008) 8272-8279
7. Sánchez-Prieto R., Quintanilla M., Cano A., Leonart M.L., Martin P., Anaya A., and Ramóny Cajal S. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 13 (1996) 1083-1092
8. Zhang X., Hussain R., Turnell A.S., Mymryk J.S., Gallimore P.H., and Grand R.J. Accumulation of p53 in response to adenovirus early region 1A sensitizes human cells to tumor necrosis factor alpha-induced apoptosis. Virology 340 (2005) 285-295
9. Bartholomeusz C., Itamochi H., Yuan L.X., Esteva F.J., Wood C.G., Terakawa N., Hung M.C., and Ueno N.T. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 65 (2005) 8406-8413
10. Madhusudan S., Tamir A., Bates N., Flanagan E., Gore M.E., Barton D.P., Harper P., Seckl M., Thomas H., Lemoine N.R., Charnock M., Habib N.A., Lechler R., Nicholls J., Pignatelli M., and Ganesan T.S. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin. Cancer Res. 10 (2004) 2986-2996
11. Yoo G.H., Hung M.C., Lopez-Berestein G., La Follette S., Ensley J.F., Carey M., Batson E., Reynolds T.C., and Murray J.L. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res. 7 (2001) 1237-1245
12. Hale T.K., and Braithwaite A.W. The adenovirus oncoprotein E1a stimulates binding of transcription factor ETF to transcriptionally activate the p53 gene. J. Biol. Chem. 274 (1999) 23777-23786
13. Itamochi H., Kigawa J., Kanamori Y., Oishi T., Bartholomeusz C., Nahta R., Esteva F.J., Sneige N., Terakawa N., and Ueno N.T. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol. Cancer Ther. 6 (2007) 227-235
14. Berk A.J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24 (2005) 7673-7685
15. Bruton R.K., Pelka P., Mapp K.L., Fonseca G.J., Torchia J., Turnell A.S., Mymryk J.S., and Grand R.J. Identification of a second CtBP binding site in adenovirus 5 E1A conserved region 3. J. Virol. 82 (2008) 8476-8486
16. Bruton R.K., Rasti M., Mapp K.L., Young N., Carter R.Z., Abramowicz I.A., Sedgwick G.G., Onion D.F., Shuen M., Mymryk J.S., Turnell A.S., and Grand R.J. C-terminal-binding protein interacting protein binds directly to adenovirus early region 1A through its N-terminal region and conserved region 3. Oncogene 26 (2007) 7467-7479
17. Su C.Q., Sham J., Xue H.B., Wang X.H., Chua D., Cui Z.F., Peng L.H., Li L.F., Jiang L.H., Wu M.C., and Qian Q.J. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J. Cancer Res. Clin. Oncol. 130 (2004) 591-603
18. Shimamoto S., Takata M., Tokuda M., Oohira F., Tokumitsu H., and Kobayashi R. Interactions of S100A2 and S100A6 with the tetratricopeptide repeat proteins, Hsp90/Hsp70-organizing protein and kinesin-light chain. J. Biol. Chem. 283 (2008) 28246-28258
19. Hong S., Paulson Q.X., and Johnson D.G. E2F1 and E2F3 activate ATM through distinct mechanisms to promote E1A-induced apoptosis. Cell Cycle 7 (2008) 391-400
20. Liao Y., Yu D., and Hung M.C. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Adv. Exp. Med. Biol. 608 (2007) 144-169
21. Su C., Na M., Chen J., Wang X., Liu Y., Wang W., Zhang Q., Li L., Long J., Liu X., Wu M., Fan X., and Qian Q. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol. Cancer Res. 6 (2008) 568-575
22. Su C., Peng L., Sham J., Wang X., Zhang Q., Chua D., Liu C., Cui Z., Xue H., Wu H., Yang Q., Zhang B., Liu X., Wu M., and Qian Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 13 (2006) 918-927
23. Nemajerova A., Talos F., Moll U.M., and Petrenko O. Rb function is required for E1A-induced S-phase checkpoint activation. Cell Death Differ. 15 (2008) 1440-1449
24. Fueyo J., Gomez-Manzano C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., Shi Y.X., Levin V.A., Yung W.K., and Kyritsis A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces antiglioma effect in vivo. Oncogene 19 (2000) 2-12
25. Sánchez-Prieto R., Quintanilla M., Cano A., Leonart M.L., Martin P., Anaya A., and Ramón y Cajal S. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 13 (1996) 1083-1092
26. Yu W., and Fang H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7 (2007) 141-148